A10255 is a complex of new thiopeptide antibiotics characterized structurally by a cyclic peptide core to which is attached a side chain composed of dehydroalanine moieties. The complex contained 80-85% factor B, 15-20% factor G, and trace amounts of factors C, D, E, F, H, and J. Taxonomic studies indicated the producing microorganism to be a strain of Streptomyces gardneri. The major portion of the antibiotic produced remained associated with the mycelial biomass, from which it was extracted with polar solvents such as aqueous methanol or aqueous acetone. Initial A10255 yields of < 2 micrograms/ml were increased to over 300 micrograms/ml in stirred reactors through strain selection, nutritional studies, and conversion of the batch fermentation to a fed-batch mode.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7164/antibiotics.45.1222 | DOI Listing |
J Antibiot (Tokyo)
November 1992
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
J Antibiot (Tokyo)
August 1992
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
A10255 is a complex of new thiopeptide antibiotics produced by Streptomyces gardneri. When stirred reactors were operated in batch mode using a defined medium with a glucose feed, 250 micrograms/ml of A10255 were produced during a four-day fermentation cycle. The linear growth phase of S.
View Article and Find Full Text PDFJ Antibiot (Tokyo)
August 1992
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
A10255 is a complex of new thiopeptide antibiotics characterized structurally by a cyclic peptide core to which is attached a side chain composed of dehydroalanine moieties. The complex contained 80-85% factor B, 15-20% factor G, and trace amounts of factors C, D, E, F, H, and J. Taxonomic studies indicated the producing microorganism to be a strain of Streptomyces gardneri.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!